Camalexin

Camalexin

SCHEMBL343413

c1ccc2c(-c3nccs3)c[nH]c2c1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.51
IMPDH2 P12268 1/20 0.51
MAPK1 P28482 1/20 0.51
MAPT P10636 9/20 0.50
SMN1; SMN2 Q16637 8/20 0.50
MEN1 O00255 8/20 0.50
KMT2A Q03164 8/20 0.50
RAB9A P51151 6/20 0.50
NPC1 O15118 6/20 0.50
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 5/20 0.49
GAA P10253 1/20 0.49
THRB P10828 2/20 0.49
ALOX15 P16050 1/20 0.49
PPARG P37231 1/20 0.49
NCOA2 Q15596 1/20 0.49
GSK3B P49841 2/20 0.48
CDK1 P06493 1/20 0.48
CCNB1 P14635 1/20 0.48
CLK1 P49759 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30668749 0.79 TGFBR1 (0.51) KMT2AGSK3BCDK5DYRK1ACDK5R1
SCHEMBL30833583 0.79 PIK3CD (0.53) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL2241248 0.79 TGFBR1 (0.51) KMT2AGSK3BCDK5DYRK1ACDK5R1
SCHEMBL5830921 0.79 PIK3CD (0.53) MAPTSMN1; SMN2MEN1KMT2ARAB9A
6-Fluorocamalexin SCHEMBL12993648 0.78 TDO2 (0.55) AR
SCHEMBL5429209 0.78 CLK1 (0.52) IMPDH2MAPTSMN1; SMN2MEN1KMT2A
5-Fluorocamalexin SCHEMBL12993647 0.78 MAP3K14 (0.52) KDM4EMAP3K14HTR2CAR
SCHEMBL26259375 0.78 PDPK1 (0.59) MAPTRAB9ANPC1ALDH1A1KDM4E
5-Methoxycamalexin SCHEMBL12993651 0.75 MAP3K14 (0.55) HSD17B10MAPK1MAPTMEN1KMT2A
6-Methoxycamalexin SCHEMBL12993653 0.75 DYRK1A (0.56) HSD17B10MAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 352 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114380815-B Plant protection camalexin derivative and preparation method and application thereof 河北工业大学 2024-05-31 CN claimed
US-20230233620-A1 HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES Kanvas Biosciences, Inc. 2023-07-27 US claimed
EP-4152959-A1 HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES Chan Zuckerberg Biohub, Inc. (US) 2023-03-29 EP claimed
US-11566260-B2 Potentiating agents for protecting plants from fungal infections UNIVERSITE D'ANGERS (FR) 2023-01-31 US claimed
CN-114380815-A Phytoalexin derivative and preparation method and application thereof 河北工业大学 2022-04-22 CN claimed
WO-2020226482-A1 SYNERGISTIC COMPOSITIONS FOR CONTROLLING PLANT PATHOGENS WITH CHITINOLYTIC MICROORGANISMS / ORGANIC ACID COMBINATIONS AND METHOD OF USE THEREOF LAI HONG HENG (MY) 2020-11-12 WO claimed
US-10405550-B2 Potentiating agents for protecting plants from fungal infections UNIVERSITE D'ANGERS (FR) 2019-09-10 US claimed
EP-2871964-B1 POTENTIATING AGENTS FOR PROTECTING PLANTS FROM FUNGAL INFECTIONS UNIV ANGERS (FR) 2019-08-21 EP claimed
US-20180020677-A1 SEED ENDOPHYTES ACROSS CULTIVARS AND SPECIES, ASSOCIATED COMPOSITIONS, AND METHODS OF USE THEREOF INDIGO AG, INC. 2018-01-25 US claimed
EP-3240391-A2 SEED ENDOPHYTES ACROSS CULTIVARS AND SPECIES, ASSOCIATED COMPOSITIONS, AND METHODS OF USE THEREOF Indigo Agriculture, Inc. (US) 2017-11-08 EP claimed
WO-2016109758-A2 SEED ENDOPHYTES ACROSS CULTIVARS AND SPECIES, ASSOCIATED COMPOSITIONS, AND METHODS OF USE THEREOF Symbiota, LLC (US) 2016-07-07 WO claimed
EP-2768510-A1 CAMALEXIN AS A TREATMENT FOR PROSTATE CANCER Clark Atlanta University (US) 2014-08-27 EP claimed
US-20140234359-A1 PLANT VIRAL VACCINES AND THERAPEUTICS VIRAL GENETICS, INC. (US) 2014-08-21 US claimed
WO-2013070401-A1 CAMALEXIN AS A TREATMENT FOR PROSTATE CANCER CLARK ATLANTA UNIVERSITY (US) 2013-05-16 WO claimed
US-20130096166-A1 CAMALEXIN AS A TREATMENT FOR PROSTATE CANCER CLARK ATLANTA UNIVERSITY (US) 2013-04-18 US claimed
WO-2013044061-A1 PLANT VIRAL VACCINES AND THERAPEUTICS THE TEXAS A&M UNIVERSITY SYSTEM (US) 2013-03-28 WO claimed
EP-1716209-B1 USE OF COMPOSITION CONTAINING INDOLYL THIAZOLIUM AZO DYES FOR DYING KERATIN FIBERS WELLA AG (DE) 2009-03-25 EP claimed
EP-1730239-B1 LIGHTENING COLORANT CONTAINING INDOLYL THIAZOLIUM AZO DYES WELLA AG (DE) 2007-05-02 EP claimed
US-12628822-B2 Plant pathogen defence elicitors UNIVERSITE LIBRE DE BRUXELLES (BE) 2026-05-19 US disclosed
EP-0259085-A1 2-Guanidino-4-arylthiazoles for treatment of peptic ulcers PFIZER INC. (US) 1988-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140234359-A1 PLANT VIRAL VACCINES AND THERAPEUTICS MAVS, BROX, ZC3HAV1 HSD17B10 3512/4885IMPDH2 2731/4885MAPK1 2851/4885
US-12628822-B2 Plant pathogen defence elicitors LPO, LCT, CHIT1 HSD17B10 1100/4885IMPDH2 1733/4885MAPK1 520/4885
US-10405550-B2 Potentiating agents for protecting plants from fungal infections ERG28, CTSA, MAN2A1 HSD17B10 3664/4885IMPDH2 2345/4885MAPK1 2010/4885
US-11566260-B2 Potentiating agents for protecting plants from fungal infections ERG28, GUSB, CTSA HSD17B10 3400/4885IMPDH2 1858/4885MAPK1 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.